Limaprost alfadex

Drug Profile

Limaprost alfadex

Alternative Names: Limaprost; Limaprost alphadex; ONO-1206; OP-1206; Opalmon; Opast; Prorenal

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma; Ono Pharmaceutical
  • Developer Dainippon Sumitomo Pharma; Ono Pharmaceutical; Sumitomo Dainippon Pharma; Yungjin Pharm Co
  • Class Peripheral vasodilators; Prostaglandins; Small molecules; Unsaturated fatty acids; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intermittent claudication; Thromboangiitis obliterans
  • Discontinued Carpal tunnel syndrome; Spondylosis

Most Recent Events

  • 16 Mar 2015 Limaprost alfadex licensed to China Chemical & Pharmaceutical Company in Taiwan
  • 03 Oct 2014 Ono Pharmaceuticals and Sumitomo Dainippon Pharma receive approval for the stability-improved formulation of limaprost for use in patients with thromboangiitis obliterans or intermittent claudication in Japan
  • 28 Jul 2014 Limaprost licensed to Meiji Seika Pharma in Thailand and Indonesia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top